New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions
出版年份 2015 全文链接
标题
New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions
作者
关键词
-
出版物
HEPATOLOGY RESEARCH
Volume 45, Issue 10, Pages E1-E11
出版商
Wiley
发表日期
2014-12-05
DOI
10.1111/hepr.12459
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC).
- (2017) Calin Cainap et al. JOURNAL OF CLINICAL ONCOLOGY
- EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2015) et al. JOURNAL OF HEPATOLOGY
- Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib
- (2014) Noriyuki Koyama et al. BMC CANCER
- Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design
- (2014) J. M. Llovet et al. CLINICAL CANCER RESEARCH
- Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial
- (2014) Masatoshi Kudo et al. HEPATOLOGY
- Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
- (2014) Andrew X. Zhu et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Mutational landscape of HCC—the end of the beginning
- (2014) Augusto Villanueva et al. Nature Reviews Clinical Oncology
- Human and Mouse VEGFA-Amplified Hepatocellular Carcinomas Are Highly Sensitive to Sorafenib Treatment
- (2014) E. Horwitz et al. Cancer Discovery
- Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma
- (2013) Kaoru Tsuchiya et al. CANCER
- A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer
- (2013) A. X. Zhu et al. CLINICAL CANCER RESEARCH
- Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study
- (2013) Jordi Bruix et al. EUROPEAN JOURNAL OF CANCER
- αB-crystallin complexes with 14-3-3ζ to induce epithelial-mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma
- (2013) Xiao-Yong Huang et al. HEPATOLOGY
- Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
- (2013) Philip J. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study
- (2013) Josep M. Llovet et al. JOURNAL OF CLINICAL ONCOLOGY
- Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
- (2013) Ann-Lii Cheng et al. JOURNAL OF CLINICAL ONCOLOGY
- The antiangiogenic ceiling in hepatocellular carcinoma: does it exist and has it been reached?
- (2013) Ghassan K Abou-Alfa et al. LANCET ONCOLOGY
- Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma
- (2012) S Hagiwara et al. BRITISH JOURNAL OF CANCER
- A Phase I Dose-Escalation Study of Regorafenib (BAY 73-4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors
- (2012) K. Mross et al. CLINICAL CANCER RESEARCH
- Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma
- (2012) Hashem B. El-Serag GASTROENTEROLOGY
- FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma
- (2012) Tokuzo Arao et al. HEPATOLOGY
- Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma
- (2012) Shunsuke Kondo et al. International Journal of Clinical Oncology
- Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naïve patients with hepatocellular carcinoma
- (2012) Beom Kyung Kim et al. LIVER INTERNATIONAL
- Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma
- (2012) Cécile Guichard et al. NATURE GENETICS
- Liver Resection and Transplantation in Hepatocellular Carcinoma
- (2012) J. Belghiti et al. Liver Cancer
- The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis
- (2011) Weon-Kyoo You et al. BMB Reports
- A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma
- (2011) Stephen L. Chan et al. CANCER
- Des-γ-Carboxyprothrombin May Be a Promising Biomarker to Determine the Therapeutic Efficacy of Sorafenib for Hepatocellular Carcinoma
- (2011) Kazuomi Ueshima et al. DIGESTIVE DISEASES
- Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma
- (2011) Masatoshi Kudo et al. EUROPEAN JOURNAL OF CANCER
- Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma
- (2011) Koji Miyahara et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Early Clinical Development of ARQ 197, a Selective, Non-ATP-Competitive Inhibitor Targeting MET Tyrosine Kinase for the Treatment of Advanced Cancers
- (2011) A. A. Adjei et al. ONCOLOGIST
- The Significance of Early Alpha-Fetoprotein Level Changes in Predicting Clinical and Survival Benefits in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib
- (2011) T. Yau et al. ONCOLOGIST
- Early Decrease in α-Fetoprotein, but Not Des-γ-Carboxy Prothrombin, Predicts Sorafenib Efficacy in Patients with Advanced Hepatocellular Carcinoma
- (2011) Teiji Kuzuya et al. ONCOLOGY
- A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma
- (2010) Fumihiko Kanai et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Targeting the HGF/c-Met Axis: State of Play
- (2010) T. A. Yap et al. MOLECULAR CANCER THERAPEUTICS
- The role of signaling pathways in the development and treatment of hepatocellular carcinoma
- (2010) S Whittaker et al. ONCOGENE
- Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis
- (2009) S J Schoenleber et al. BRITISH JOURNAL OF CANCER
- PDGF-C Mediates the Angiogenic and Tumorigenic Properties of Fibroblasts Associated with Tumors Refractory to Anti-VEGF Treatment
- (2009) Yongping Crawford et al. CANCER CELL
- Angiogenesis in liver disease
- (2009) Mercedes Fernández et al. JOURNAL OF HEPATOLOGY
- Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma
- (2008) Ai-Wu Ke et al. HEPATOLOGY
- Novel advancements in the management of hepatocellular carcinoma in 2008
- (2008) Josep M. Llovet et al. JOURNAL OF HEPATOLOGY
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Angiogenesis selectively requires the p110α isoform of PI3K to control endothelial cell migration
- (2008) Mariona Graupera et al. NATURE
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection
- (2007) Klaus Juergen Schmitz et al. JOURNAL OF HEPATOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started